Sinopharm Group Co. Ltd. (SHTDY)
Sinopharm Group Co. Ltd. operates in the Medical - Distribution industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $9.43, up 0.11% on the session, giving a market capitalisation of $5.89B. On trailing twelve-month figures it carries a trailing P/E of 5.65, a net margin of 1.2%. Its beta of 0.45 implies it has historically moved less than the broad market.
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Sinopharm Group Co. Ltd. is most often compared with the following Healthcare names: